Elisabetta Bonzano MD, PhD
LightNews LightNews
banner
elisabettabonzano.bsky.social
Elisabetta Bonzano MD, PhD
@elisabettabonzano.bsky.social
250 followers 27 following 100 posts
Radiation Oncologist, MD, PhD Fondazione IRCCS Policlinico San Matteo @UniPv - MIUR Qualified Associate Professor - PhD in Experimental Medicine
Posts Replies Media Videos
elisabettabonzano.bsky.social
📌 Primary Results From ASCENT-03 ✨

PFS: 9.7 mo vs 6.9 mo, HR 0.62
ORR: 48% vs 46%
DOR: 12.2 vs 7.2 mo
OS immature: HR 0.98
PFS2: 18.2 vs 14.0, HR 0.70

Dr. @Javier Cortès at Proffered paper session 2
#ESMO25 🇩🇪 📍Berlin
@oncoalert.bsky.social #OncoalertAF @nejm.org
🔗 lnkd.in/diBhSjXG
October 19, 2025 at 1:50 PM
elisabettabonzano.bsky.social
📌 Primary results from the randomised, phase III TROPION-Breast02 trial✨

🔸OS HR 0.79 (95% Cl 0.64-0.98); P=0.0291
🔹PFS by BICR HR 0.57 (95% CI 0.47-0.69); Р<0.0001
🔸 ≥5-month improvement in both median OS and PFS

Proffered paper session 2

#ESMO25 @oncoalert.bsky.social #OncoalertAF
October 19, 2025 at 1:47 PM
elisabettabonzano.bsky.social
📌 Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

🔗nejm.org/doi/full/10.10…

👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1)

@oncoalert.bsky.social #OncoAlertAF #BreastCancer #RadOnc
June 5, 2025 at 9:31 PM
elisabettabonzano.bsky.social
📌 Opting Out of Therapy for Early-Stage Breast Cancer: How Far Might We Go?
✨Prof @icromeattini.bsky.social
👉🏻 How to Integrate Radiotherapy Into Current Treatment Concepts❗️
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #RadOnc
June 3, 2025 at 7:26 AM
elisabettabonzano.bsky.social
📌 NRG-BR003: A randomized phase Ill trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative
TNBC.
✨Vicente Valero #ASCO25
@oncoalert.bsky.social #OncoAlertAF
June 3, 2025 at 7:24 AM
elisabettabonzano.bsky.social
📌 The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/ HER2- breast cancer.
✨Erica L. Mayer, MD, MPH, FASCO
✔️Rapid Oral Abstract Session
Breast Cancer-Local/Regional/ Adjuvant
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #Day3
June 3, 2025 at 7:23 AM
elisabettabonzano.bsky.social
📌 Highlights of the Day II
👉🏻Breast Cancer-Metastatic
✨@maryam_lustberg 👏🏻
🟩 Key takeaways HR+ MBC
🟦 Key takeaways in HER2 positive MBC
🟨 Key Takeaways Metastatic TNBC
@oncoalert.bsky.social #OncoAlertAF #ASCO25
June 3, 2025 at 7:21 AM
elisabettabonzano.bsky.social
📌 Do We "Node" What to Do About the Axilla❓
Great discussion👏🏻
✨Mediget Teshome, MD, FACS, MPH
@oncoalert.bsky.social #OncoAlertAF #ASCO25
June 3, 2025 at 7:19 AM
elisabettabonzano.bsky.social
📌 LBA Session❗️
✨DESTINY-Breast09 results ✅
Stunning presentation ✨ @stolaney1.bsky.social 👏🏻

👉🏻 Median PFS:
🔸T-DXd + P: 40.7 mo
🔸THP: 26.9 mo
HR 0.56, p<0.001
👉🏻ORR 85.1%

@oncoalert.bsky.social #OncoAlertAF #ASCO25
June 3, 2025 at 7:13 AM
elisabettabonzano.bsky.social
📌Great discussant #ESTRO25

prof @icromeattini.bsky.social 👏🏻👏🏻

✨ Late-Breaking Papers ✨

👉🏻10y FAST-Forward randomised trial
👉🏻 DBCG Skagen trial 1
@oncoalert.bsky.social
May 3, 2025 at 9:15 AM
elisabettabonzano.bsky.social
📌Proud to share our latest review: “Current Treatment Paradigms for Advanced Melanoma with Brain Metastases” 🧠

mdpi.com/1422-0067/26/8…

👉🏻 Optimizing local & systemic strategies, tackling key clinical questions, and paving the way for tailored therapies.
@oncoalert.bsky.socia#OncoAlertAFAF
April 19, 2025 at 8:29 AM
elisabettabonzano.bsky.social
📌 Awareness of genomic testing among patients with breast cancer in Europe 🧬

www.sciencedirect.com/science/arti...

@oncoalert.bsky.social #OncoAlertAF @breastdocuk.bsky.social
@csabadegi.bsky.social
March 30, 2025 at 8:46 AM
elisabettabonzano.bsky.social
📌 Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial
@oncoalert.bsky.social #OncoAlertAF

thegreenjournal.com/article/S0167-…
March 29, 2025 at 7:46 AM
elisabettabonzano.bsky.social
📌 Selective Elimination of Breast Surgery for Invasive Breast Cancer
A Nonrandomized Clinical Trial

jamanetwork.com/journals/jam...
@oncoalert.bsky.social
March 28, 2025 at 6:13 PM
elisabettabonzano.bsky.social
📌 Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer

jamanetwork.com/journals/jam...

@oncoalert.bsky.social
March 28, 2025 at 5:46 PM
elisabettabonzano.bsky.social
📌 Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism

molecularcancer.biomedcentral.com/articles/10.11…
@oncoalert.bsky.social
March 28, 2025 at 5:44 PM
elisabettabonzano.bsky.social
📌 Smoking increases breast toxicity despite adjuvant hypofractionated IMRT in early breast cancer
👉🏻 addressing lifestyle factors to improve patient outcomes and quality of life 🚭

ro-journal.biomedcentral.com/articles/10.11…

@oncoalert.bsky.social
March 28, 2025 at 5:43 PM
elisabettabonzano.bsky.social
📌 Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation

sciencedirect.com/science/articl…
@oncoalert.bsky.socia#OncoAlertAFAF
March 27, 2025 at 1:52 PM
elisabettabonzano.bsky.social
📌 Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated RTOG/NRG and EORTC Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial
redjournal.org/article/S0360-…
@oncoalert.bsky.social
March 19, 2025 at 9:17 PM
elisabettabonzano.bsky.social
📌Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial
@oncoalert.bsky.social
February 27, 2025 at 6:37 AM
elisabettabonzano.bsky.social
📌 Comparison of 18F-FET-PET- and MRI-based target definition for re-irradiation treatment of recurrent diffuse glioma 🧠

sciencedirect.com/science/articl…
@oncoalert.bsky.social
February 27, 2025 at 6:35 AM
elisabettabonzano.bsky.social
📌 Pre-Operative Single Fraction Stereotactic Partial Breast Irradiation (S-PBI) for Early-Stage Breast Cancer Patients with Gammapod Technology: Pathological Findings and Ki-67 Evaluation
redjournal.org/article/S0360-…
@oncoalert.bsky.social
February 23, 2025 at 9:39 AM
elisabettabonzano.bsky.social
📌 Long-Term Outcomes of Radiation Monotherapy Versus Combined Radiation Monotherapy + Hormone Therapy in Low-Risk Early-Stage Breast Cancer Patients 70 Years or Older After Breast-Conserving Surgery

@oncoalert.bsky.social #OncoAlertAF @ijrobp.bsky.social #BreastCancer
February 9, 2025 at 12:17 PM
elisabettabonzano.bsky.social
📌 Whole genome sequencing powered ctDNA sequencing for breast cancer detection

annalsofoncology.org/article/S0923-…
@oncoalert.bsky.social
February 6, 2025 at 12:55 PM
elisabettabonzano.bsky.social
Day Three #OncoAlertColloquium 🚨 #BreastCancer
REGISTER for FREE HERE👉 buff.ly/42IcWl2 Fatima Cardoso 🇵🇹 👏🏻 of @ABCGlobalAll
Covering Brain Metastasis in Breast Cancer: Year in Review @oncoalert.bsky.social
February 6, 2025 at 7:17 AM